Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Breast Neoplasms 3Vulvar Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Bile Duct Neoplasms 1

Interventions

Methods 3Trastuzumab 2Radiotherapy 2Early Intervention, Educational 2Behavior Therapy 2tivozanib 1tipifarnib 1nanocis 1entinostat 1atezolizumab 1Technetium-99 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Ritonavir 1Quality of Life 1Psychiatric Rehabilitation 1Patient Reported Outcome Measures 1Observation 1Nivolumab 1Molecular Diagnostic Techniques 1Interviews as Topic 1Interleukin-12 Subunit p35 1Interleukin-12 1Infracyanine green 1Indocyanine Green 1Indinavir 1Immunotherapy 1Immunohistochemistry 1Hysterectomy 1Gene Rearrangement 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vulvar Neoplasms × tivozanib × Breast × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡